Preprints.org · Nov 13, 2026

Genetic Proxied GLP1R Agonist Exposure and Risk of Psoriasis and Atopic Dermatitis: A Drug-Target Mendelian Randomization Study

By Wan Y, Tahir N, Hasen A et al.

Background: Glucagon-like peptide-1 receptor (GLP1R) agonists are widely used for the treatment of diabetes and obesity and have demonstrated anti-inflammatory and immunomodulatory properties. However, the causal relationship between GLP1R agonists and inflammatory skin diseases is still unclear. Objectives: To investigate the causal relationship between genetically proxied GLP1R agonist exposure and the risk of inflammatory skin diseases, specifically psoriasis and atopic dermatitis (AD), in individuals of European ancestry using a drug-target Mendelian randomization approach. Methods: The available cis-eQTLs for drug target gene (GLP1R) were used as proxies for exposure to GLP1R agonists. Obesity and type 2 diabetes mellitus (T2DM) were used as positive controls to ensure the validity of the genetic instruments. Mendelian randomization (MR) was performed to assess the causal association of genetically proxied GLP1R agonist exposure with 2 inflammatory skin diseases, psoriasis and AD, from the IEU OpenGWAS database. The IVW estimates were meta-analyzed and further validated using independent GWAS summary statistics from the FinnGen Consortium (R12). Results: A total of 22 significant cis-eQTL single-nucleotide polymorphisms were included as genetic instruments. Positive control analysis revealed that GLP1R agonists were significantly associated with obesity (OR = 0.85, 95% CI: 0.77–0.94, p < 0.01) and T2DM (OR = 0.56, 95% CI: 0.51–0.62, p < 0.01), which is consistent with the meta-analysis. MR analysis indicated that genetically predicted GLP1R agonist exposure was a risk factor for both psoriasis (OR = 1.85, 95% CI: 1.56–2.20, p < 0.01) and AD (OR = 1.39, 95% CI: 1.26–1.54, p < 0.01). Validation using data from the FinnGen Consortium yielded results consistent with the meta-analysis findings. Conclusions: Our study suggests that GLP1R agonists may increase the risk of psoriasis and AD. These findings provide genetic evidence to inform pharmacovigilance strategies for the clinical use of GLP1R agonists and offer novel insights for the development of targeted therapeutic interventions in inflammatory dermatoses.

doi.org/10.20944/preprints202611.1499.v1Open accessPopulations

AgingResearch.News